Biogen Idec commissioned Charles River Associates to examine how access to innovative treatments for multiple sclerosis (MS) varies across European countries, the factors explaining this, and the policy lessons that can be drawn. MS is a disorder of the central nervous system (brain and spinal cord) affecting over 500,000 Europeans. CRA found that significant inequalities in access to MS treatments persist in 2013. To download the PDF version of this report click the link below.
Greg Bell ranked among The Top 50 Leaders in Healthcare Consulting of 2022
Vice President and Practice Leader of the global Life Sciences Practice, Gregory K. Bell has been ranked by The Consulting Report in The Top 50 Leaders in...